Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Williams Companies Inc (WMB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Williams Companies Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Williams Companies Inc trades at $74.77 (market cap $91.82B). The key difference: Williams Companies Inc is far larger — about 20.4× ACADIA Pharmaceuticals Inc.'s market cap, and Williams Companies Inc pays a 2.8% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | WMB | |
|---|---|---|
Market Cap | $4.49B | $91.82B |
Sector | Health | Energy |
52-Week High | $28.06 | $79.40 |
52-Week Low | $20.06 | $56.51 |
Enterprise Value | $3.69B | $121.21B |
Dividend Yield | — | 2.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Williams Companies (WMB) trades at $75.08, up 2.65% on the day, approaching its 52-week high of $80.08. The stock shows strong profitability with a 23.4% net income margin and 21.95% ROE, though valuation ratios like P/E of 31.94 appear elevated. Recent news highlights a potential $5.5 billion acquisition of Momentum Midstream to expand natural gas infrastructure, while technical indicators signal a bearish trend despite neutral oscillators.
WMB presents a mixed outlook: robust cash flow growth and a 79% analyst buy rating support upside to the $86.55 consensus target, but high debt levels and recent earnings misses pose risks. The stock's current price near resistance at $75 suggests near-term consolidation, with long-term growth hinging on successful integration of acquisitions and stable energy demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Williams Companies Inc
Williams is a midstream energy company that owns and operates the large Transco and Northwest pipeline systems and associated natural gas gathering, processing, and storage assets. In August 2018, the firm acquired the remaining 26% ownership of its limited partner, Williams Partners.
Read more on WMB →
